Published in Epidemiol Infect on February 01, 1990
Reducing alcohol consumption. Comparing three brief methods in family practice. Can Fam Physician (1997) 2.20
Structural and Computational Biology in the Design of Immunogenic Vaccine Antigens. J Immunol Res (2015) 0.85
Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep (2016) 0.79
Adverse events after hepatitis B vaccination. CMAJ (1992) 0.75
Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med (1986) 4.51
Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature (1982) 3.82
A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology (1982) 2.74
Clinical evaluation of a recombinant hepatitis B vaccine. Lancet (1984) 1.33
Hepatitis B vaccines--to switch or not to switch. JAMA (1987) 1.23
Expression of hepatitis B surface antigen in yeast. Dev Biol Stand (1983) 0.97
Persistence of vaccine-induced antibodies to hepatitis B surface antigen and the need for booster vaccination in adult subjects. Postgrad Med J (1987) 0.94
Immunogenicity of recombinant yeast hepatitis B vaccine. Lancet (1985) 0.89
Comparative immunogenicity of plasma and recombinant hepatitis B virus vaccines in homosexual men. JAMA (1989) 0.87
Comparative multicentre study of the immunogenicity of different hepatitis B vaccines in healthy volunteers. Postgrad Med J (1987) 0.86
Comparison of the immunogenicity of reduced doses of two recombinant DNA hepatitis B vaccines in New Zealand children. J Med Virol (1989) 0.81
Immunogenicity of yeast-derived hepatitis B vaccines in young adults. Postgrad Med J (1987) 0.80
The assessment of immunity against hepatitis B after vaccination. J Biol Stand (1986) 0.80
Hepatitis B. Taiwan plans mass vaccination. Nature (1984) 0.80
Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med (1994) 3.73
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet (1995) 2.43
Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol (1985) 2.06
Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis (1994) 1.93
Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol (1999) 1.86
Elevated levels of serum-soluble CD14 in human immunodeficiency virus type 1 (HIV-1) infection: correlation to disease progression and clinical events. Blood (1998) 1.83
CXC-chemokines, a new group of cytokines in congestive heart failure--possible role of platelets and monocytes. Cardiovasc Res (2000) 1.74
Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol (2001) 1.71
Oligoclonal measles virus-specific IgG antibodies isolated from cerebrospinal fluids, brain extracts, and sera from patients with subacute sclerosing panencephalitis and multiple sclerosis. Scand J Immunol (1976) 1.66
Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab (1999) 1.61
Myocardial gene expression of leukaemia inhibitory factor, interleukin-6 and glycoprotein 130 in end-stage human heart failure. Eur J Clin Invest (2001) 1.55
IL-10 in HIV infection: increasing serum IL-10 levels with disease progression--down-regulatory effect of potent anti-retroviral therapy. Clin Exp Immunol (1999) 1.55
Clopidogrel increases expression of chemokines in peripheral blood mononuclear cells in patients with coronary artery disease: results of a double-blind placebo-controlled study. J Thromb Haemost (2006) 1.55
Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation (1999) 1.53
A micro assay for mouse and human interferon. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 1.50
Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol (1999) 1.50
Primary immunodeficiency diseases in Norway. J Clin Immunol (2000) 1.48
Elevated plasma levels of reduced homocysteine in common variable immunodeficiency--a marker of enhanced oxidative stress. Eur J Clin Invest (1997) 1.48
Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation (1998) 1.46
[Immunomodulating treatment in advanced heart failure--effect of intravenous immunoglobulin]. Tidsskr Nor Laegeforen (2001) 1.40
Synergistic effect in viral-bacterial infection. I. Combined infection of the respiratory tract in mice with parainfluenza virus and Hemophilus influenza. J Infect Dis (1968) 1.36
Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J (1998) 1.35
Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. J Infect Dis (1994) 1.33
Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol (2000) 1.32
Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation (2001) 1.29
Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: association with immunological hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab (1998) 1.29
Viral infection as a cause of acute peripheral facial palsy. Arch Otolaryngol (1976) 1.28
Human cytomegalovirus suppression of and latency in early hematopoietic progenitor cells. Blood (1996) 1.26
Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol (2001) 1.18
Interferon in suction blister fluid from psoriatic lesions. Br J Dermatol (1983) 1.17
Natural killer (NK) cell activity of peripheral blood, synovial fluid, and synovial tissue lymphocytes from patients with rheumatoid arthritis and juvenile rheumatoid arthritis. Ann Rheum Dis (1982) 1.16
Interferon in the serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders. Acta Neurol Scand (1976) 1.14
Mouse fibroblast interferon modifies Salmonella typhimurium infection in infant mice. Infect Immun (1984) 1.14
Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood (1994) 1.12
Deficient lymphoid cell-mediated, PHA-induced cytotoxicity in rheumatoid arthritis patients. Scand J Immunol (1975) 1.10
Detection of latent varicella zoster virus DNA and human gene sequences in human trigeminal ganglia by in situ amplification combined with in situ hybridization. Arch Virol (1995) 1.10
Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol (2007) 1.08
Protein kinase A type I antagonist restores immune responses of T cells from HIV-infected patients. FASEB J (1998) 1.07
Both IgA subclasses are reduced in parotid saliva from patients with AIDS. Clin Exp Immunol (1991) 1.05
Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol (1999) 1.05
Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol (2002) 1.03
Lifelong treatment with gammaglobulin for primary antibody deficiencies: the patients' experiences of subcutaneous self-infusions and home therapy. J Adv Nurs (1995) 1.02
Phagocytic and bactericidal activities of peritoneal and alveolar macrophages from mice. J Med Microbiol (1969) 1.02
Decreased vitamin A levels in common variable immunodeficiency: vitamin A supplementation in vivo enhances immunoglobulin production and downregulates inflammatory responses. Eur J Clin Invest (2000) 1.01
Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol (2008) 1.01
Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation (2001) 1.01
Effect of human leukocyte interferon on invasiveness of Salmonella species in HEp-2 cell cultures. Infect Immun (1983) 1.01
Enhanced interleukin-10 production in response to Mycobacterium avium products in mononuclear cells from patients with human immunodeficiency virus infection. J Infect Dis (1998) 1.00
Raised serum neopterin levels in patients with primary hypogammaglobulinaemia; correlation to other immunological parameters and to clinical and histological features. Clin Exp Immunol (1992) 1.00
Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure--modulatory effect of intravenous immunoglobulin. J Am Coll Cardiol (2001) 1.00
Elevated serum levels of interleukin-4 and interleukin-6 in patients with common variable immunodeficiency (CVI) are associated with chronic immune activation and low numbers of CD4+ lymphocytes. Clin Immunol Immunopathol (1994) 0.98
Immunological features in a case of subacute sclerosing panencephalitis treated with transfer factor. Scand J Immunol (1973) 0.98
Long-term outcome of chronic hepatitis C virus infection in primary hypogammaglobulinaemia. QJM (1999) 0.97
Synergistic effect in viral-bacterial infection. 2. Influence of viral infection on the phagocytic ability of alveolar macrophages. Acta Pathol Microbiol Scand B Microbiol Immunol (1970) 0.97
Subclass composition and J-chain expression of the 'compensatory' gastrointestinal IgG cell population in selective IgA deficiency. Clin Exp Immunol (1992) 0.96
In vitro mitogen stimulation of synovial fluid lymphocytes from rheumatoid arthritis and juvenile rheumatoid arthritis patients: dissociation between the response to antigens and polyclonal mitogens. Scand J Immunol (1978) 0.96
Synergistic effect in viral-bacterial infection. 3. Histopathological changes in the trachea of mice following viral and bacterial infection. Acta Pathol Microbiol Scand B Microbiol Immunol (1971) 0.95
Chemokines in myocardial failure -- pathogenic importance and potential therapeutic targets. Clin Exp Immunol (2001) 0.95
Levels of circulating adhesion molecules in congestive heart failure and after heart transplantation. Am J Cardiol (1998) 0.94
Circulating levels of RANTES in human immunodeficiency virus type 1 infection: effect of potent antiretroviral therapy. J Infect Dis (1998) 0.94
Cytomegalovirus DNA concentration in plasma predicts development of cytomegalovirus disease in kidney transplant recipients. Clin Microbiol Infect (2002) 0.94
Virological and immunological effects of antioxidant treatment in patients with HIV infection. Eur J Clin Invest (2000) 0.94
Inflammatory imbalance between IL-10 and TNFalpha in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest (2002) 0.94
Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication. Clin Exp Immunol (2009) 0.93
Gene expression analysis of peripheral T cells in a subgroup of common variable immunodeficiency shows predominance of CCR7(-) effector-memory T cells. Clin Exp Immunol (2004) 0.93
Chromatography of RNA-DNA complexes on hydroxyapatite. A method for the separation of the complementary strands in T2 DNA. Eur J Biochem (1970) 0.92
Impaired in vitro survival of monocytes from patients with HIV infection. Clin Exp Immunol (1990) 0.92
A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation (2000) 0.92
Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol (2005) 0.91
HIV-1 infection in Norwegian family before 1970. Lancet (1988) 0.91
Effect of human gamma interferon on invasiveness of Salmonella typhimurium in HEp-2 cell cultures. J Interferon Res (1985) 0.91
Raised serum levels of interleukin-18 is associated with disease progression and may contribute to virological treatment failure in HIV-1-infected patients. Clin Exp Immunol (2003) 0.90
Bacteriophage typing of Staphylococcus aureus using a single concentration of phage (100 x RTD). Acta Pathol Microbiol Scand (1966) 0.90
Elevated serum calprotectin levels in HIV-infected patients: the calprotectin response during ZDV treatment is associated with clinical events. J Acquir Immune Defic Syndr (1994) 0.90
Production of immune interferon (type II) in cocultures of mouse peritoneal macrophages and syngeneic tumour cells. Scand J Immunol (1981) 0.90
Disseminated Mycobacterium avium complex infection in AIDS: immunopathogenic significance of an activated tumor necrosis factor system and depressed serum levels of 1,25 dihydroxyvitamin D. J Infect Dis (1996) 0.89
Hepatitis A in young Norwegian drug addicts and prison inmates. Infection (1988) 0.89
Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost (2000) 0.89
Measles virus antibodies in serum and cerebrospinal fluid in patients with multiple sclerosis and other neurological disorders, with special reference to measles antibody synthesis within the central nervous system. J Neurol Sci (1975) 0.89
Sequence analysis of HIV-1 group O from Norwegian patients infected in the 1960s. Virology (1997) 0.88
Enhanced generation of reactive oxygen species in monocytes from patients with common variable immunodeficiency. Clin Exp Immunol (1994) 0.88
On the adsorption of Australia antigen to a colloidal silica, and some possible applications. Acta Pathol Microbiol Scand B Microbiol Immunol (1972) 0.87
Effects of interferon-alpha/beta and interferon-gamma preparations on phagocytosis by mouse peritoneal macrophages. Scand J Immunol (1984) 0.87
C-reactive protein and delayed hypersensitivity in juvenile rheumatoid arthritis. Scand J Rheumatol (1978) 0.87
Pathogenesis of Sendasi virus infection in mice. On the possible role of interferon on the development of disease. Acta Pathol Microbiol Scand B (1980) 0.87
Effect of interferon preparations on the uptake of non-opsonized Escherichia coli by mouse peritoneal macrophages. Acta Pathol Microbiol Scand B (1981) 0.87
Nonspecific oral immunity in individuals with HIV infection. J Acquir Immune Defic Syndr (1992) 0.86
Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools. Scand J Infect Dis (1991) 0.86
The spectrum of hepatobiliary disease in primary hypogammaglobulinaemia. J Intern Med (1999) 0.86
Glucosylated nucleotide sequences from T2-bacteriophage deoxyribonucleic acid. Biochem J (1964) 0.86
Prevalence of neuropsychological deficit in HIV infection. Incipient signs of AIDS dementia complex in patients with AIDS. Acta Neurol Scand (1991) 0.86
Complex effects of interferon-alpha on the cytokine network in HIV infection--possible contribution to immunosuppression. Cytokine (2001) 0.86
Intraepithelial gamma/delta T cells in duodenal mucosa are related to the immune state and survival time in AIDS. J Virol (1996) 0.86
Additive effects of IL-2 and protein kinase A type I antagonist on function of T cells from HIV-infected patients on HAART. AIDS (1999) 0.85
Adhesion molecules in common variable immunodeficiency (CVID)--a decrease in L-selectin-positive T lymphocytes. Clin Exp Immunol (1998) 0.85
Altered IgG-subclass distribution in lymph node cells and serum of adults infected with human immunodeficiency virus (HIV). Clin Exp Immunol (1989) 0.85